XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study.
Phase of Trial: Phase IV
Latest Information Update: 01 May 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms XIENCE-V-USA
- Sponsors Abbott Laboratories
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
- 16 Sep 2010 One-year results will be presented at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington D.C., according to an Abbott Laboratories media release.
- 21 May 2010 Results will be presented at EuroPCR 2010 according to an Abbott media release. Data will include one-year primary endpoint data on blood clots (stent thrombosis) and dual antiplatelet usage.